-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26

Benzinga·06/25/2026 14:10:39
Listen to the news
Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy rating and lowers Price Target of $26.